Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Bayer Nisocor commercialization decision pending; Adalat CC jumped to $120 mil. U.S. sales in 1994.

Executive Summary

NISOLDIPINE U.S. COMMERCIALIZATION DECISION PENDING AT BAYER three months after FDA's Feb. 2 approval for the extended-release calcium channel blocker. The Bayer Pharmaceutical Division (previously Miles) says it is continuing to evaluate options for nisoldipine, which currently carries the brandname Nisocor, including outlicensing and comarketing. Nisoldipine extended-release is marketed in many countries outside the U.S.
Advertisement
Advertisement
UsernamePublicRestriction

Register

PS026148

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel